看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
# k- u; U: y8 V4 l# ^4 b" C2 U6 B' Y% {
% l/ R! v! U" D7 rCurrently available feasibility data for possible combination strategies. 0 W8 x& v# c# S" H
————————————————————————————————
& f* g# E) \/ m- L" Y' rCombination Feasibility according to preliminary data
/ D: u/ [1 z! L——————————————————————————————————# @4 k. x1 s" G: k+ H$ j& d
Bevacizumab + sorafenib Yes, reduced dose
9 ?* H9 S4 K. {Bevacizumab + sunitinib† No
. @& _8 ?* E3 N. K9 Q" XBevacizumab + temsirolimus Yes ; L m; y4 @) J+ W$ Z3 C: X* G
Bevacizumab + everolimus Yes
) X. F4 P8 ~( e8 G& G! \Sorafenib + sunitinib ?
" E1 E8 L# h% ^# t# bSorafenib + temsirolimus Yes, reduced dose 7 X+ n( y' S: a3 R
Sorafenib + everolimus Yes, reduced dose
+ e, a, x) o+ |. i& D+ V1 wSunitinib + temsirolimus† No & h$ P* @9 l7 m. `2 w
Sunitinib + everolimus ?
1 u+ E5 e q* i' S z0 M$ ^- lTemsirolimus + everolimus ? ) l$ [& K( Y. @- ~5 ^
————————————————————
- n) M7 P" R, R3 O†Led to US FDA warning.
+ l+ b4 ^4 N; [0 H7 {?: As yet unattempted combination.
+ X; I$ v n4 s1 v- t0 v+ ` |